Share on Facebook Share on Twitter Email
Answers.com

Emergent BioSolutions

 
Hoover's Company Profiles:

Emergent BioSolutions Inc.

Home > Library > Business & Finance > Hoover's Profiles
(NYSE:EBS)
Contact Information
Emergent BioSolutions Inc.
2273 Research Blvd., Ste. 400
Rockville, MD 20850
MD Tel. 301-795-1800
Fax 301-795-1899

Type: Public
On the web: http://www.emergentbiosolutions.com
 Employees: 767
Employee growth: 17.6%

Emergent BioSolutions protects your thorax against anthrax. The company develops and produces vaccines that treat or protect against infectious diseases and bio-agents. The company supplies BioThrax (the US's only FDA-approved anthrax vaccine) primarily to the departments of Defense and Health and Human Services (HHS). Its biodefense unit is also developing a post-exposure treatment for anthrax and a preventive vaccine for botulinum toxin. For commercial markets, Emergent BioSolutions is working on therapies and vaccines for such infectious diseases as typhoid, tuberculosis, hepatitis B, and chlamydia. Chairman and CEO Fuad El-Hibri controls half of the company.

Key numbers for fiscal year ending December, 2010:
Sales: $286.2M
One year growth: 21.9%
Net income: $51.7M
Income growth: 66.0%

Officers:
Chairman and CEO: Fuad El-Hibri
President, COO, and Director: Daniel J. Abdun-Nabi
SVP Finance and Administration, CFO, and Treasurer: R. Don Elsey

Competitors:
Crucell
Elusys Therapeutics
Human Genome Sciences

Search unanswered questions...

Enter a question here...
Search: All sources Community Q&A Reference topics

Wikipedia on Answers.com:

Emergent BioSolutions

Top
Home > Library > Miscellaneous > Wikipedia
Emergent BioSolutions
Industry Pharmaceuticals, Healthcare
Founded 2004
Founder(s) Fuad El-Hibri
Headquarters Rockville, Maryland
Key people CEO Fuad El-Hibri, President & COO Daniel J. Abdun-Nabi
Products BioThrax® (Anthrax Vaccine Adsorbed)
Revenue increase US$257.90 million (2010)[1]
Net income increase US$51.7 million (2010)[1]
Website www.emergentbiosolutions.com

Emergent BioSolutions (NYSE: EBS) is a multinational biopharmaceutical company headquartered in Rockville, Maryland. Emergent develops vaccines and therapeutics targeting infectious diseases, oncology and autoimmune disorders. Founded as BioPort Corporation in 1998, the company was named Emergent BioSolutions in 2004. Since the early 2000s, Emergent has expanded its product development, including research and development of products through joint ventures with its most well-known product being an anthrax vaccine.

Contents

History

In 1998, the BioPort Corporation was founded to acquire an anthrax vaccine manufacturing facility in Lansing, Michigan, and other assets of the Michigan Biologics Products Institute, formerly owned by the Michigan Department of Public Health.[2] In addition to the Lansing facility, BioPort acquired the license to produce anthrax vaccine for the U.S. Department of Defense.[3] After corporate restructuring in 2004, BioPort and its subsidiary Antex Biologics became wholly owned subsidiaries of Emergent BioSolutions Inc.[4] In November 2006, Emergent held its initial public offering (IPO) on the New York Stock Exchange.[5]

Overview

Emergent BioSolutions focuses on the development and manufacture of vaccines and therapeutics for the prevention or treatment of disease.[6] Fuad El-Hibri, the chairman and CEO of Emergent BioSolutions, [7] has led the company since its founding as BioPort Inc.[2][8] The company's headquarters is in Rockville, Maryland.[9]

Product development

In 2006 and 2007, Emergent had carried out development of medications and vaccines for the treatment of typhoid, hepatitis B and streptococcus,[9][10] for which development is no longer being pursued.[11] As of July 2011, Emergent's product development pipeline includes product candidates targeting infectious diseases, oncology and autoimmune disorders.[11]

BioThrax (Anthrax Vaccine Adsorbed)

BioThrax (Anthrax Vaccine Adsorbed) is a vaccine licensed by the U.S. Food and Drug Administration.[12] Following a study by scientists from the Centers for Disease Control and Prevention,[13] on December 19, 2008, Emergent received final FDA licensing for use of BioThrax five doses for intramuscular injection.[14] On February 11, 2009, the company announced that it had been granted a license to distribute BioThrax in India.[15] Later in 2009, Emergent received approval from the FDA to extend the shelf life of its anthrax vaccine from three to four years.[16] In 2011, BioThrax was approved for sale in Singapore by the Singapore Health Sciences Authority.[17]

Acquisitions

Emergent has added to its product pipeline through the acquisition of other biotechnology and pharmaceutical companies, including Antex Biologics Inc., a pharmaceutical research and development company, in 2003,[18] and Microscience Ltd. (based in the United Kingdom) in 2005.[19] In August 2006, Emergent purchased Vivacs GmbH, a biotechnology company based in Munich, Germany.[20] On March 6, 2008, Emergent completed the acquisition of a group of anthrax monoclonal antibodies from Avanir Pharmaceuticals.[21] On May 5, 2008, Emergent acquired patents and processes of VaxGen, Inc., of Livermore, California, including VaxGen's anthrax vaccine program.[22][23] Emergent acquired Trubion Pharmaceuticals in October 2010, providing Emergent with oncology and autoimmune disease treatment candidates.[24] In 2011, it acquired the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy from TenX BioPharma, Inc.[25]

References

  1. ^ a b "Emergent BioSolutions Reports Financial Results for Full Year 2010". Reuters.com. Reuters. 10 March 2011. http://www.reuters.com/article/2011/03/10/idUS258427+10-Mar-2011+BW20110310. Retrieved 11 July 2011. 
  2. ^ a b "Lansing laboratory may begin anthrax vaccine shipments". The Michigan Daily. 23 January 2002. http://www.michigandaily.com/content/lansing-laboratory-may-begin-anthrax-vaccine-shipments. Retrieved 30 June 2011. 
  3. ^ Williams, Thomas D. (18 May 2001). "Shays: Pentagon Acted Inappropriately". The Hartford Courant. http://www.courant.com/topic/hc-anthrax-051801,0,214733.story. Retrieved 30 June 2011. 
  4. ^ "Antex Biologics Awarded NIAID Grant to Continue Development of Helicobacter pylori Vaccine". BusinessWire. 9 July 2004. http://www.businesswire.com/news/home/20040709005348/en/Antex-Biologics-Awarded-NIAID-Grant-Continue-Development. Retrieved 5 July 2011. 
  5. ^ Cowan, Lynn (15 November 2006). "Stock of vaccine maker has weak opening after IPO". Dow Jones Newswires. The Associated Press. 
  6. ^ "Emergent BioSolutions Secures Orphan Drug Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalation Anthrax". Health & Beauty Close-Up. 9 November 2010. 
  7. ^ Shapiro, Andy (29 May 2008). "Md. firm to buy Protein Sciences". New Haven Register. 
  8. ^ "Emergent BioSolutions CEO joins board of U.S. Chamber of Commerce". Washington Business Journal. 13 June 2010. 
  9. ^ a b Ramstack, Tom (16 October 2007). "BioSolutions posts healthy progress". The Washington Times: p. C10. 
  10. ^ "Form S1/A Emergent BioSolutions Inc.". Corporate IR.net. Thomson Reuters. 30 October 2006. http://media.corporate-ir.net/media_files/irol/20/202582/irkit/S1A.pdf. Retrieved 20 July 2011. 
  11. ^ a b "Emergent BioSolutions Portfolio as of July 2011" (PDF). Emergent BioSolutions. July 2011. http://emergentbiosolutions.com/images/EBS_pipeline.pdf. Retrieved 11 July 2011. 
  12. ^ Echols, Tucker (14 July 2010). "Emergent BioSolutions wins $107M HHS contract". Washington Business Journal. 
  13. ^ Lauerman, John (30 September 2008). "Emergent's Anthrax Vaccine Effective With Fewer Doses in Study". Bloomberg. http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aVi7uxzenRnY&refer=home. Retrieved 11 July 2011. 
  14. ^ "Emergent BioSolutions Gets FDA Nod For Anthrax Vaccine supplemental BLA - Update". RTT News. 19 December 2008. http://www.rttnews.com/Content/BreakingNews.aspx?Node=B1&Id=808016%20&Category=Breaking%20News. Retrieved 11 July 2011. 
  15. ^ "Local Briefing". The Washington Post. 13 February 2009. http://www.washingtonpost.com/wp-dyn/content/article/2009/02/12/AR2009021203623.html. Retrieved 11 July 2011. 
  16. ^ "Emergent BioSolutions Receives FDA Approval Extending Shelf Life of BioThrax (Anthrax Vaccine Adsorbed) to 4 Years". Business Wire. 10 June 2009. http://www.businesswire.com/news/google/20090610005924/en. Retrieved 11 July 2011. 
  17. ^ Clabaugh, Jeff (24 June 2011). "Emergent gets entry to Singapore". Washington Business Journal. http://www.bizjournals.com/washington/news/2011/06/24/emergent-gets-entry-to-singapore.html. Retrieved 22 July 2011. 
  18. ^ "BioPort Corporation Completes Purchase of Assets of Antex Biologics". BusinessWire. 3 June 2003. http://www.businesswire.com/news/home/20030603005782/en/BioPort-Corporation-Completes-Purchase-Assets-Antex-Biologics. Retrieved 5 July 2011. 
  19. ^ "Emergent acquires vaccine company.". BIOTECH Patent News. 1 June 2005. ISSN 0898-2813. 
  20. ^ "Emergent BioSolutions Expands Presence in Germany". PR Newswire US. 3 August 2006. 
  21. ^ "Avanir Divests Anthrax mAb Program to Emergent BioSolutions in Deal Worth $1.75M". Genetic Engineering & Biotechnology News. 6 March 2008. http://www.genengnews.com/gen-news-highlights/avanir-divests-anthrax-mab-program-to-emergent-biosolutions-in-deal-worth-1-75m/31614011/. Retrieved 12 October 2011. 
  22. ^ "VaxGen sells anthrax vaccine candidate to Emergent BioSolutions". Forbes. Thomson Reuters. 5 May 2008. http://www.forbes.com/feeds/afx/2008/05/05/afx4967820.html. Retrieved 11 July 2011. 
  23. ^ "VaxGen wraps up sale of anthrax assets". San Francisco Business Times. 5 May 2008. http://www.bizjournals.com/sanfrancisco/stories/2008/05/05/daily1.html. Retrieved 11 July 2011. 
  24. ^ "Emergent BioSolutions Completes Acquisition Of Trubion Pharmaceuticals". The Street. 28 October 2010. http://www.thestreet.com/story/10904468/1/emergent-biosolutions-completes-acquisition-of-trubion-pharmaceuticals.html. Retrieved 12 July 2011. 
  25. ^ "Emergent BioSolutions Continues Expansion into Cancer with mAb Acquisition from TenX". Genetic Engineering & Biotechnology News. 6 June 2011. http://www.genengnews.com/gen-news-highlights/emergent-biosolutions-continues-expansion-into-cancer-with-mab-acquisition-from-tenx/81245251/. Retrieved 22 July 2011. 

External links


This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)

 
 
Related topics:
VaxGen, Inc. (Public Company)
Emergent
Anthrax vaccines

Related answers:
What are emergent trees? Read answer...
What are rainforest emergents? Read answer...
What is an emergent theory? Read answer...

Help us answer these:
What is emergent values?
What is an emergent leader?
What is emergent flux?

Post a question - any question - to the WikiAnswers community:

 

Copyrights:

Hoover's Company Profiles. © 2012 Hoover's, Inc. All rights reserved.  Read more
Wikipedia on Answers.com. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Emergent BioSolutions.  Read more

Related answers
» More
Answer these
» More
Follow us
Facebook Twitter
YouTube